Department of Chemical & Biological Engineering, Drexel University, Philadelphia, Pennsylvania, United States of America.
Department of Clinical Chemistry, University of Amsterdam location AMC, Amsterdam, The Netherlands.
PLoS One. 2021 Apr 1;16(4):e0249603. doi: 10.1371/journal.pone.0249603. eCollection 2021.
The particle size distribution (PSD) of extracellular vesicles (EVs) and other submicron particles in biofluids is commonly measured by nanoparticle tracking analysis (NTA) and tunable resistive pulse sensing (TRPS). A new technique for measuring the PSD is microfluidic resistive pulse sensing (MRPS). Because specific guidelines for measuring EVs together with other particles in biofluids with MRPS are lacking, we developed an operating procedure to reproducibly measure the PSD. The PSDs of particles in human plasma, conditioned medium of PC3 prostate cancer cell line (PC3 CM), and human urine were measured with MRPS (nCS1, Spectradyne LLC) to investigate: (i) the optimal diluent that reduces the interfacial tension of the sample while keeping EVs intact, (ii) the lower limit of detection (LoD) of particle size, (iii) the reproducibility of the PSD, (iv) the optimal dilution for measuring the PSD, and (v) the agreement in measured concentration between microfluidic cartridges with overlapping detection ranges. We found that the optimal diluent is 0.1% bovine serum albumin (w/v) in Dulbecco's phosphate-buffered saline. Based on the shape of the PSD, which is expected to follow a power-law function within the full detection range, we obtained a lower LoD of 75 nm for plasma and PC3 CM and 65 nm for urine. Normalized PSDs are reproducible (R2 > 0.950) at dilutions between 10-100x for plasma, 5-20x for PC3 CM, and 2-4x for urine. Furthermore, sample dilution does not impact the dilution-corrected concentration when the microfluidic cartridges are operated within their specified concentration ranges. PSDs from microfluidic cartridges with overlapping detection ranges agreed well (R2 > 0.936) and when combined the overall PSD spanned 5 orders of magnitude of measured concentration. Based on these findings, we have developed operating guidelines to reproducibly measure the PSD of EVs together with other particles in biofluids with MRPS.
生物流体中外泌体(EVs)和其他亚微米颗粒的粒径分布(PSD)通常通过纳米颗粒跟踪分析(NTA)和可调电阻脉冲感应(TRPS)进行测量。一种新的测量 PSD 的技术是微流控电阻脉冲感应(MRPS)。由于缺乏使用 MRPS 测量生物流体中 EVs 与其他颗粒的具体指南,我们开发了一种可重现测量 PSD 的操作程序。使用 MRPS(nCS1,Spectradyne LLC)测量人血浆、PC3 前列腺癌细胞系(PC3 CM)条件培养基和人尿中的颗粒 PSD,以研究:(i)在保持 EV 完整的同时减少样品界面张力的最佳稀释剂,(ii)粒径的检测下限(LoD),(iii)PSD 的重现性,(iv)最佳的 PSD 测量稀释度,以及(v)具有重叠检测范围的微流控芯片之间测量浓度的一致性。我们发现最佳的稀释剂是 0.1%牛血清白蛋白(w/v)在 Dulbecco 的磷酸盐缓冲盐水中。基于 PSD 的形状,预计在全检测范围内遵循幂律函数,我们得到了血浆和 PC3 CM 的下限 LoD 为 75nm,尿液为 65nm。在血浆的 10-100x、PC3 CM 的 5-20x 和尿液的 2-4x 稀释度之间,归一化 PSD 具有可重复性(R2 > 0.950)。此外,当微流控芯片在其指定的浓度范围内运行时,样品稀释不会影响稀释校正后的浓度。具有重叠检测范围的微流控芯片的 PSD 一致性很好(R2 > 0.936),当组合在一起时,整个 PSD 跨越了测量浓度的 5 个数量级。基于这些发现,我们已经制定了操作指南,以使用 MRPS 可重现地测量生物流体中 EVs 与其他颗粒的 PSD。